In 1999, the Japan Diabetes Society (JDS) launched the previous version of the diagnostic criteria of diabetes mellitus, in which JDS took initiative in adopting glycated haemoglobin (HbA1c) as an adjunct to the diagnosis of diabetes. In contrast, in 2009 the International Expert Committee composed of the members of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) manifested the recommendation regarding the use of HbA1c in diagnosing diabetes mellitus as an alternative to glucose measurements based on the update evidences indicating that HbA1c has several advantages as a marker of chronic hyperglycemia [1] [2] [3] . The JDS extensively evaluated the usefulness and feasibility of more extended use of HbA1c in the diagnosis of diabetes based on Japanese epidemiological data, and then the ''Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus'' was published in the Diabetology International [4] and Journal of Diabetes Investigation [5] . The new diagnostic criterion in Japan came into effect on July 1, 2010. According to the new version of the criteria, HbA1c (JDS) C6.1% is now considered to indicate a diabetic type, but the previous diagnosis criteria of high plasma glucose (PG) levels to diagnose diabetes mellitus also need to be confirmed. Those are as follows: (1) FPG C126 mg/dL (7.0 mmol/L), (2) 2-h PG C200 mg/dL (11.1 mmol/L) during an OGTT, or (3) casual PG C200 mg/dL (11.1 mmol/L). If both PG criteria and HbA1c in patients have met the diabetic type, those patients are immediately diagnosed to have diabetes mellitus [4, 5] .
In the report, the HbA1c measurements in Japan are well calibrated with Japanese-Clinical-Laboratory-Use Certified Reference Material (JCCRM). The certified values are determined by a high resolution type ion-exchange High Performance Liquid Chromatography (HPLC) (KO 500 method) and certified using the designated comparison method (DCM) of the Japan Society of Clinical Chemistry (JSCC) and the JDS. After incorporating a proportional bias correction to the value anchored to the peptide mapping method of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the DCM actually measures b-N-mono-deoxyfructosyl hemoglobin and has an intercept approximately equal to zero against the peptide mapping method of IFCC in measuring fresh raw human blood samples. Furthermore, standardization of HbA1c in Japan was initiated in 1993, and the serial reference materials from JDS Lot 1 to JDS Lot 4 are well certified using the DCM until now. In the new diagnosis criteria [4, 5] , the new cut-off point of HbA1c (JDS) for diagnosis of diabetes mellitus is 6.1%, which is equivalent to the internationally used HbA1c (NGSP) 6.5%, as HbA1c (NGSP) (%) is reported to be equivalent to 1.019 9 HbA1c (JDS)% ? 0.3%, which is reasonably estimated by the equation of HbA1c (JDS)% ? 0.4%, as the difference between the two equations is within error of HbA1c measurements (2-3%).
However, on October 1, 2011, the Reference Material Institute for Clinical Chemistry Standards (ReCCS, Kanagawa, Japan) was certified as an Asian Secondary Reference Laboratory (ASRL) using the KO 500 method and the ref- Tables 1  and 2 . 
